{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:12Z","timestamp":1793065812516,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113537","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:03:54Z","timestamp":1730437434000},"page":"113537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"special_numbering":"P3","title":["Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8358-3704","authenticated-orcid":false,"given":"Nabeela","family":"Siddeeque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelmaksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah S.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-2641","authenticated-orcid":false,"given":"Rami M.","family":"Elshazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal S.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-3787","authenticated-orcid":false,"given":"Eman A.","family":"Toraih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.113537_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031851","article-title":"A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113537_b0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.intimp.2024.113537_b0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4103\/NRR.NRR-D-23-02106","article-title":"Mitochondrial therapeutics and mitochondrial transfer for neurodegenerative diseases and aging","volume":"20","author":"Ng","year":"2025","journal-title":"Neural Regen. Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.113537_b0020","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.metabol.2016.05.018","article-title":"Role of metabolism in neurodegenerative disorders","volume":"65","author":"Procaccini","year":"2016","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.intimp.2024.113537_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054354","article-title":"Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance","volume":"24","author":"Ezkurdia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2024.113537_b0030","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3390\/cimb45080420","article-title":"Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications","volume":"45","author":"Caturano","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113537_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2024.113537_b0040","first-page":"Cd012990","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2024.113537_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.intimp.2024.113537_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.intimp.2024.113537_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2024.113537_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"issue":"17","key":"10.1016\/j.intimp.2024.113537_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113537_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem. Int."},{"issue":"9","key":"10.1016\/j.intimp.2024.113537_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091861","article-title":"The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.113537_b0080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113537_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176936","article-title":"Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease","volume":"982","author":"Verma","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"Pt B","key":"10.1016\/j.intimp.2024.113537_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.intimp.2024.113537_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2024.113537_b0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2017.11.017","article-title":"GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes","volume":"100","author":"Gault","year":"2018","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.intimp.2024.113537_b0105","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"2","key":"10.1016\/j.intimp.2024.113537_b0110","article-title":"Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation","volume":"11","author":"Ashok","year":"2022","journal-title":"Antioxidants (basel)"},{"issue":"10","key":"10.1016\/j.intimp.2024.113537_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101449","article-title":"The Role of Microglia in the Development of Neurodegenerative Diseases","volume":"9","author":"Lee","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.intimp.2024.113537_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12929-024-01025-6","article-title":"Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice","volume":"31","author":"Wang","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"17","key":"10.1016\/j.intimp.2024.113537_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179351","article-title":"Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management","volume":"25","author":"Delrue","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2024.113537_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12102205","article-title":"Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior","volume":"12","author":"Antmen","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2024.113537_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.730378","article-title":"Editorial: Brain Insulin Resistance in Neurodevelopmental and Neurodegenerative Disorders: Mind the Gap!","volume":"15","author":"Dierssen","year":"2021","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/j.intimp.2024.113537_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113084","article-title":"Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes","volume":"11","author":"M\u00f8ller","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2024.113537_b0145","doi-asserted-by":"crossref","first-page":"e20230032","DOI":"10.1590\/1980-5764-dn-2023-0032","article-title":"Brain insulin resistance and Alzheimer's disease: a systematic review","volume":"18","author":"Andrade","year":"2024","journal-title":"Dement Neuropsychol"},{"issue":"8","key":"10.1016\/j.intimp.2024.113537_b0150","first-page":"e43882","article-title":"Exploring the Complex Connection Between Diabetes and Cardiovascular Disease: Analyzing Approaches to Mitigate Cardiovascular Risk in Patients With Diabetes","volume":"15","author":"Jyotsna","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2024.113537_b0155","article-title":"Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2024.113537_b0160","doi-asserted-by":"crossref","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"issue":"7","key":"10.1016\/j.intimp.2024.113537_b0165","first-page":"e65910","article-title":"Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular","volume":"16","author":"Rajagopal","year":"2024","journal-title":"Renal, and Neural Systems: an Updated Narrative Review, Cureus"},{"issue":"3","key":"10.1016\/j.intimp.2024.113537_b0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.intimp.2024.113537_b0175","doi-asserted-by":"crossref","unstructured":"J. Huang, F. Wu, L. Chen, J. Yu, W. Sun, Z. Nie, H. Liu, F. Yang, C. Zheng, CT-Based Radiomics Helps to Predict Residual Lung Lesions in COVID-19 Patients at Three Months after Discharge, Diagnostics (Basel) 11(10) (2021).","DOI":"10.3390\/diagnostics11101814"},{"issue":"17","key":"10.1016\/j.intimp.2024.113537_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174308","article-title":"Efficacy and Optimal Pressure of Continuous Positive Airway Pressure in Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer","volume":"14","author":"Park","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.113537_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jss.2022.03.017","article-title":"The Association Between Metabolic Derangement and Wound Complications in Elective Plastic Surgery","volume":"278","author":"Sergesketter","year":"2022","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.intimp.2024.113537_b0190","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ijbiomac.2017.10.090","article-title":"Effects of polysaccharides from the base of Flammulina Velutipes stipe on growth of murine RAW264.7, B16F10 and L929 cells","author":"Chen","year":"2018","journal-title":"Int J Biol Macromol 107(Pt b)"},{"issue":"2","key":"10.1016\/j.intimp.2024.113537_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020234","article-title":"Resident Self-Tissue of Pro-inflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Gata1(low) Mice","volume":"12","author":"Zingariello","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.intimp.2024.113537_b0200","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.radcr.2022.03.055","article-title":"Metastatic renal cell carcinoma presenting as subcutaneous nodule","volume":"17","author":"Haque","year":"2022","journal-title":"Radiol Case Rep"},{"issue":"41","key":"10.1016\/j.intimp.2024.113537_b0205","doi-asserted-by":"crossref","first-page":"26673","DOI":"10.1039\/D2RA04938D","article-title":"Divergent copper-catalyzed syntheses of 3-carboxylpyrroles and 3-cyanofurans from O-acetyl oximes and \u03b2-ketoesters\/nitriles","volume":"12","author":"Almaraz-Ortiz","year":"2022","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.intimp.2024.113537_b0210","first-page":"e44763","article-title":"Exploring the Potential of Anti-diabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review","volume":"15","author":"Koshatwar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2024.113537_b0215","doi-asserted-by":"crossref","unstructured":"D. Kothandan, D.S. Singh, G. Yerrakula, B. D, P. N, B.V. Santhana Sophia, R. A, S. Ramya Vg, K. S, J. M, Advanced Glycation End Products-Induced Alzheimer's Disease and Its Novel Therapeutic Approaches: A Comprehensive Review, Cureus 16(5) (2024) e61373.","DOI":"10.7759\/cureus.61373"},{"key":"10.1016\/j.intimp.2024.113537_b0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.peptides.2017.11.014","article-title":"Role of islet peptides in beta cell regulation and type 2 diabetes therapy","volume":"100","author":"Khan","year":"2018","journal-title":"Peptides"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:22:29Z","timestamp":1733959349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924020599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"alternative-id":["S1567576924020599"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113537","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113537"}}